Medicine guide

HUMIRA

As listed in the register: HUMIRA 20 mg, solution injectable en seringue préremplie

20 mg · solution injectable

  • Prescription only
Active substance
Adalimumab
Made by
ABBVIE DEUTSCHLAND (ALLEMAGNE)

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Adalimumab-aacf). It describes the substance, not this exact product.

Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors.

Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement.

Peak level after5.5 days
Half-life2 wk
Mostly cleared after≈ 10 weeksfive half-lives — our arithmetic
PeakHalf gone10 weeks0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-08

Safety of the active substance

From the US prescribing label for the same active substance (Adalimumab-aacf). It describes the substance, not this exact product.

Serious warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning.

Most common side effects

The most common adverse reaction with adalimumab was injection site reactions.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

Details

Made byABBVIE DEUTSCHLAND (ALLEMAGNE)
Active substanceAdalimumab
Strength20 mg
Formsolution injectable
Routesous-cutanée
Dispensing (as stated by the register)prescription réservée aux spécialistes et services PEDIATRIE · prescription réservée aux spécialistes et services HEPATO/GASTRO-ENTEROLOGIE · prescription réservée aux spécialistes et services MEDECINE INTERNE · prescription réservée aux spécialistes et services OPHTALMOLOGIE · prescription réservée aux spécialistes et services RHUMATOLOGIE · prescription réservée aux spécialistes et services DERMATOLOGIE · liste I
MarketedYes, according to the register
Authorisation procedureProcédure centralisée
EU numberEU/1/03/256
Name in the registerHUMIRA 20 mg, solution injectable en seringue préremplie
Packs2 seringue(s) préremplie(s) en verre de 0,2 ml avec tampon(s) alcoolisé(s)
CIS62975984
CIP133400930126165

Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician

Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).

Other strengths and forms

5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.